Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandeep Dutta

Showing results (51-60 of 114) with videos related to

Pageof 12
Sort By:
The AAPS Journal|January 9, 2015
Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteersGuohua An, Wei Liu, W Rachel Duan, et al.
Clinical Pharmacokinetics|February 26, 2017
Clinical Pharmacokinetics of ParitaprevirRajeev M Menon, Akshanth R Polepally, Amit Khatri, et al.
Epilepsy & Behavior : E&B|February 14, 2006
Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrationsRonald C Reed, Sandeep Dutta, John H Cavanaugh, et al.
The AAPS Journal|February 14, 2015
Erratum to: population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteersGuohua An, Wei Liu, W Rachel Duan, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2016
Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and RilpivirineAmit Khatri, Sandeep Dutta, Martin Dunbar, et al.
Biopharmaceutics & Drug Disposition|July 22, 2014
Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimensGuohua An, Wei Liu, David A Katz, et al.
Clinical Pharmacology : Advances and Applications|December 17, 2020
Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]Michael Z Liao, Johannes Kast, Marloes Berkhout, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 24, 2022
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanomaMalidi Ahamadi, Johannes Kast, Po-Wei Chen, et al.
Clinical Drug Investigation|May 31, 2007
Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic DrugsKenneth W Sommerville, Sandeep Dutta, Victor Biton, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 8, 2016
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease InhibitorsAmit Khatri, Sandeep Dutta, Haoyu Wang, et al.
Pageof 12

Showing results (51-60 of 114) with videos related to

Sort By:
Pageof 12
The AAPS Journal|January 9, 2015
Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteersGuohua An, Wei Liu, W Rachel Duan, et al.
Clinical Pharmacokinetics|February 26, 2017
Clinical Pharmacokinetics of ParitaprevirRajeev M Menon, Akshanth R Polepally, Amit Khatri, et al.
Epilepsy & Behavior : E&B|February 14, 2006
Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrationsRonald C Reed, Sandeep Dutta, John H Cavanaugh, et al.
The AAPS Journal|February 14, 2015
Erratum to: population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteersGuohua An, Wei Liu, W Rachel Duan, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2016
Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and RilpivirineAmit Khatri, Sandeep Dutta, Martin Dunbar, et al.
Biopharmaceutics & Drug Disposition|July 22, 2014
Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimensGuohua An, Wei Liu, David A Katz, et al.
Clinical Pharmacology : Advances and Applications|December 17, 2020
Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]Michael Z Liao, Johannes Kast, Marloes Berkhout, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 24, 2022
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanomaMalidi Ahamadi, Johannes Kast, Po-Wei Chen, et al.
Clinical Drug Investigation|May 31, 2007
Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic DrugsKenneth W Sommerville, Sandeep Dutta, Victor Biton, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 8, 2016
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease InhibitorsAmit Khatri, Sandeep Dutta, Haoyu Wang, et al.
Pageof 12